Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR (TAR)
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia
About this trial
This is an interventional prevention trial for Acute Lymphoblastic Leukemia focused on measuring allogeneic stem cell transplant, malignant diseases, Acute lymphoblastic leukemia, acute myelogenous leukemia, Chronic myelogenous leukemia, myelodysplastic syndrome, Hodgkin lymphoma, non-Hodgkin lymphoma, myeloproliferative disorder, non-malignant disease
Eligibility Criteria
INCLUSION CRITERIA:
Inclusion Criteria for Donors:
- Related donor of bone marrow or peripheral blood stem cell product
- Age 3 to 70 years
- Informed consent form signed and sent to Research Coordinator
Inclusion Criteria for Recipients:
- Patient with acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, myeloproliferative disorder, Hodgkin lymphoma, non-Hodgkin lymphoma, or a non-malignant disease requiring allogeneic stem cell transplant
- Age between 3 and 70 years
- Informed consent form signed and sent to Research Coordinator
EXCLUSION CRITERIA:
Exclusion Criteria for Donors:
- Allergy to tetanus vaccine
- Pregnant or lactating
- Has received tetanus booster within preceding 12 months
Exclusion Criteria for Recipients to Receive FIRST Tetanus Immunization:
- Allergy to tetanus vaccine
- Has received tetanus booster within preceding 12 months
- Has active malignancy (not in remission)
Exclusion Criteria for Recipients to Receive SUBSEQUENT Tetanus Immunization:
- Allergy to tetanus vaccine
- Active, acute graft vs. host disease (GVHD) greater than or equal to grade II or chronic graft vs. host disease (GVHD)
- Disease relapse - less than 75% donor chimerism (peripheral blood or bone marrow)
- Active infection (bacterial, viral, fungal) or fever (temperature greater than 100.5 celsius)
Sites / Locations
- Texas Childen's Hospital
- The Methodist Hospital
Arms of the Study
Arm 1
Experimental
Single arm: Tetanus Toxoid
SCT Donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest